ClinicalTrials.gg
RecruitingNCT07434544Updated Oct 20, 2026

Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)

An interventional study of Cherry Sports Drink in Non-Nutritive Sweetener, Type 1 Diabetes and type1diabetes, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 15 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 20, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
15 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 190 open to participants now, 257 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.

Planned enrollment
863rd of 1,242
20 · median 40
Started
2026
with 61 others
No phase
614 of 1,458
99 open now
Primary completion
2028-12
later than 211 of 256 live
Registered
1,415th of 1,458
by date

Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 863rd largest by planned enrollment of the 1,242 interventional ones that give a count, is one of 62 that started in 2026, is one of 614 with no phase, reaches primary completion later than 211 of the 256 other live ones, and was the 1,415th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

190 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:

184 more — sign in →

All 190 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 15 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, or all of them as a file.
02

Study summary

This project will apply a novel non-nutritive sweetener (NNS) dietary assessment tool with measurement of circulating NNS levels in a pediatric population, allowing correlation of NNS exposure to clinically meaningful cardiometabolic health outcomes.

Read the detailed description

The purpose of this project is to learn how NNS affects the health of the blood vessels.

Type 1 diabetes (T1D) is an autoimmune disease that requires lifelong dependence on prescribed insulin. Scientists know that if an individual has T1D, they are at greater risk of having cardiovascular disease than people who do not have diabetes.

To help manage diabetes, individuals may talk with their doctor about adjusting what they normally eat or drink. Doctors typically ask that individuals avoid foods and drinks with lots of sugar in them. In response to this, individuals might drink diet drinks or eat snacks or other foods that are sugar-free. Sugar-free drinks and foods have NNS which help things taste sweet without impacting their blood glucose.

Concern exists that consuming NNS may make individuals more at risk for developing cardiovascular disease. Although the American Heart Association advises against long-term NNS consumption, about 20% of all beverages consumed by children contain NNS.

Currently, there are no scientifically backed questionnaires to assess how much NNS someone is consuming. As well, there are no commercially available lab tests to determine how much NNS is in someone's blood. This makes it difficult to draw associations or causal relationships between NNS exposure and health outcomes.

By conducting this project, the investigators hope to gain knowledge to potentially inform and revise care guidelines for individuals with T1D and ultimately lead to improved nutritional recommendations and clinical care of children.

03

Conditions studied

  • Non-Nutritive Sweetener
  • Type 1 Diabetes
  • type1diabetes
  • Type 1 Diabetes Mellitus

Keywords

  • Non-Nutritive Sweeteners
  • Type 1 Diabetes
  • Cardiometabolic
  • Long standing
04

Who can participate

Ages eligible
15 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 15-24 years
  2. Clinical diagnosis of type 1 diabetes, requiring insulin therapy, of ≥ 1 to \< 10 years duration.
  3. Last available ≤ 8.5% (obtained by chart review in Children's Wisconsin Diabetes Clinic patients or verbally by individuals not receiving diabetes care at Children's Wisconsin)
  4. Current use of an FDA approved automated insulin delivery (AID) system
  5. Willing to consume a 12 ounce Gatorade G Zero Glacier Cherry drink in less than 10 minutes
  6. Willing and able to give or have parent or legal guardian provide informed consent if the subject is \< 18 years of age

Exclusion criteria

Exclusion Criteria:

  1. Any disease other than type 1 diabetes that affects glucose, sex , or fat metabolism such as polycystic ovary syndrome or hypercortisolism
  2. Any medication use that may affect glucose, sex steroid, or fat metabolism such as metformin or glucocorticoids
  3. Half or full sibling already participating in this study
  4. Known cardiovascular disease such as hypertension or atherosclerosis, and/or use of an anti-hypertensive medication
  5. Known hyperlipidemia, defined as LDL ≥ 160 mg/dL, and/or use of lipid-lowering medication, such as statin therapy
  6. Known renal disease or microalbuminuria, and/or use of angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARBs) for microalbuminuria
  7. Known diabetic retinopathy or neuropathy
  8. Raynaud's phenomenon or other vascular disease
  9. Obesity and/or body habitus that precludes completion of the flow-mediated brachial ultrasound study (generally, > 40 kg/m2 in adults) - this is at study team's discretion.
  10. Pregnancy or lactation
  11. Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Sports Drink - Participants will drink a cherry sports drink within 10 minutes.

    Dietary Supplement: Cherry Sports Drink

Interventions

  • Dietary supplementCherry Sports Drink

    12 oz bottle (1 1/2 cups) of Gatorade G Zero Glacier Cherry™ Sports Drink

    Also known as: Gatorade Zero Glacier Cherry™

06

What researchers measure

Primary outcomes

  1. Change in "in vivo" endothelial function and vascular stiffness

    Brachial artery ultrasound will measure flow-mediated dilation % (FMD%) at baseline and 1 hour after drinking a non-nutritive sweetened sports drink.

    Time frame: 2 years (duration of study)

Secondary outcomes

  1. Associations of circulating NNS levels with self-reported food frequency assessments

    A food frequency survey has been developed of the most common categories of NNS containing foods and beverages. Participants will complete the food frequency survey to select the frequency by which they consumed a given product and the most common serving size over the past month.

    Time frame: 2 years (duration of study)

  2. Impact of chronic NNS dietary consumption on cardiovascular health

    Changes 1-hour after NNS consumption from baseline will be measured by carotid-femoral pulse wave velocity, baseline flow velocity, and hyperemic flow velocity

    Time frame: 2 years (duration of study)

  3. Impact of chronic NNS dietary consumption on metabolic health

    Changes 1-hour after NNS consumption from baseline will be measured by blood lipids, blood glucose, and blood pressure

    Time frame: 2 years (duration of study)

  4. Impact of chronic NNS dietary consumption of T1D specific glycemic control

    Changes 1-hour after NNS consumption from baseline will be measured by 14-day continuous glucose monitor (CGM) data and 14-day insulin data for total daily dose and % basal insulin

    Time frame: 2 years (duration of study)

07

Study locations

1 of 1 sites recruiting
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
    • Susanne M Cabrera, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2028, 28 months after the start.

Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 28 months is above that.

Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 25, 2026
StartActual
Aug 5, 2026was Jun 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
Medical College of Wisconsin is now Recruiting
Oct 20, 2026
Start date
Jun 1, 2026→Aug 5, 2026 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Not yet recruiting→Recruiting
    Medical College of Wisconsin is now Recruiting
    Start date Jun 1, 2026→Aug 5, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07434544
Responsible party
Susanne Cabrera (Doctor of Medicine; Endocrinology, Medical College of Wisconsin) — Principal investigator
First posted
Feb 25, 2026
Start date
Aug 5, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Susanne M Cabrera, MD
Contact
T1dinfo@mcw.edu
414-955-4903

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion